Udenafil

Udenafil is an orally active phosphodiesterase type 5 inhibitor, part of the same drug class as sildenafil, tadalafil, vardenafil and avanafil, that is used chiefly to treat erectile dysfunction and has also been studied for the urinary symptoms of benign prostatic hyperplasia ^[1]. Like the others in its class, it improves erectile function by acting on the nitric-oxide signalling pathway in the smooth muscle of the penis.

The drug was developed in South Korea by Dong-A Pharmaceutical and is sold under the brand name Zydena. It gained approval in Korea and has been marketed in several other countries, including Russia and the Philippines, but it has not been approved for use in the United States by the Food and Drug Administration ^[1][2]. Clinical trials reported significant improvement in erectile function over placebo, and the drug was found to be generally well tolerated ^[2].

Chemically udenafil is a pyrimidine-based sulfonamide. Its pharmacokinetics give it a useful profile; peak plasma levels are reached roughly one to one and a half hours after a dose, and it has a comparatively long plasma half-life of about eleven to thirteen hours, so it acts fairly quickly yet lasts a long time ^[1]. It is highly bound to plasma proteins, metabolised in the liver mainly by the enzyme CYP3A4, and eliminated largely through the bile. This combination supports both as-needed use before activity and regular once-daily dosing, and studies show that food delays absorption somewhat without meaningfully reducing overall exposure ^[3].

At the molecular level udenafil raises levels of the signalling molecule cyclic GMP in vascular smooth muscle, relaxing blood vessels and increasing blood flow.

As with other PDE5 inhibitors, common side effects include headache, facial flushing, nasal congestion and indigestion, and the class must not be combined with nitrate medicines because of the risk of a dangerous drop in blood pressure. Udenafil is a prescription drug where it is approved and is not available as an approved medicine in countries such as the United States ^[1].

Udenafil is prescription only and is not FDA approved in the United States. Typical effects are facial flushing, headache, nasal congestion, indigestion and eye redness. Taking it with any nitrate or with the pulmonary drug riociguat can cause a dangerous fall in blood pressure, so those combinations are off limits, and it should be used cautiously with alpha blockers and other blood pressure medicines. Rare but serious risks include priapism and sudden changes in vision or hearing, including a rare optic condition called NAION. Strong CYP3A4 inhibitors can raise its levels.

Udenafil was developed by the South Korean company Dong-A Pharmaceutical as a domestically discovered phosphodiesterase type 5 inhibitor for erectile dysfunction, entering the Korean market around 2005 under the brand name Zydena. It emerged during the wave of second-generation PDE5 inhibitors that followed the commercial success of sildenafil, and Dong-A designed it with pharmacokinetics intended to combine a reasonably quick onset with a comparatively long duration of action, supporting both on-demand and once-daily dosing.

The drug went on to gain approval in Korea and a number of other countries, though it has not been approved in the United States. Beyond erectile dysfunction, its manufacturer and academic collaborators have investigated udenafil for benign prostatic hyperplasia and, more recently, for cardiovascular and pulmonary indications. It has been studied in patients with single-ventricle Fontan circulation, reflecting broader interest in the long-acting PDE5 inhibitor class for conditions driven by impaired vascular relaxation.

Udenafil has a solid reputation as an effective and well-tolerated PDE5 inhibitor, and it is often highlighted for a pharmacological profile that balances onset and duration in a way that suits flexible dosing. A meta-analysis of randomized controlled trials concluded that it significantly improves erectile function scores compared with placebo, with adverse events that were generally mild, most commonly flushing and headache, and no serious events reported.

As a nationally developed drug, it holds a prominent place in Korean urology and has expanded internationally on the strength of that evidence. Its investigation in heart and pulmonary circulation conditions has added a further dimension of scientific interest, suggesting uses beyond sexual medicine. Users should note that it is not available in every market and remains unapproved in the United States, but within its approved territories it is a respected member of its class.